Effective chemotherapy for relapsed lymphoma
Author Information
Author(s): Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman A R, Wotherspoon A, Catovsky D
Primary Institution: Royal Marsden Hospital, London and Surrey, UK
Hypothesis
Is the combination of gemcitabine, cisplatin, and methylprednisolone an effective treatment for relapsed and refractory lymphoma?
Conclusion
The GEM-P regimen is effective in treating patients with relapsed and refractory lymphoma, achieving a response rate of 79%.
Supporting Evidence
- The best-achieved response rate was 79%, with a complete response rate of 21%.
- In patients with chemo-resistant disease, the response rate was 63%.
- Myelosuppression was the main toxicity observed.
- Only one patient experienced neutropenic sepsis.
- Grade 3 or 4 nonhaematological toxicity was minimal.
Takeaway
This study shows that a special mix of medicines can help people with tough-to-treat lymphoma feel better and live longer.
Methodology
The study evaluated the GEM-P regimen in 41 heavily pretreated patients with relapsed and refractory lymphoma, measuring response rates and toxicity.
Potential Biases
Potential bias due to the lack of a control group and the observational nature of the study.
Limitations
The study included a small sample size and was limited to heavily pretreated patients.
Participant Demographics
Median age was 42 years, with a majority having nodular sclerosing Hodgkin's lymphoma or diffuse large B-cell lymphoma.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 64–91
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website